期刊文献+

利拉鲁肽联合二甲双胍在2型糖尿病患者中的防治效果及对机体免疫的影响研究 被引量:40

Effect of liraglutide combined with metformin on type 2 diabetes mellitus and its effect on immune function
暂未订购
导出
摘要 目的:探讨利拉鲁肽联合二甲双胍对2型糖尿病患者中的防治效果及对机体免疫的影响。方法:将150例2型糖尿病患者按入院顺序随机分为观察组与对照组,每组75例。对照组应用二甲双胍治疗,观察组应用利拉鲁肽联合二甲双胍治疗。分析两组患者治疗15周后临床治疗效果、平均体质指数、血糖水平(餐后2h血糖、糖化血红蛋白、空腹血糖)、免疫球蛋白水平(IgA、IgG、IgM)以及不良反应发生率等指标。结果:(1)治疗前,两组患者的平均体质指数、餐后2h血糖、糖化血红蛋白、空腹血糖、IgA、IgG、IgM等比较无统计学意义(P>0.05);治疗后,观察组患者IgA、IgG水平显著低于对照组、IgM水平显著高于对照组(P<0.05),观察组患者平均体质指数、餐后2h血糖、糖化血红蛋白、空腹血糖水平显著优于对照组(P<0.05);(2)观察组治疗总有效率为94.67%(71/75),对照组治疗总有效率为77.33%(58/75),观察组治疗总有效率明显高于对照组(P<0.05);(3)观察组不良反应发生率为4.00%(3/75),对照组不良反应发生率为5.33%(4/75),两组患者不良反应发生率比较无统计学意义(P>0.05)。结论:利拉鲁肽联合二甲双胍在2型糖尿病患者中的防治效果显著,能有效提高机体免疫功能。 Objective:To analyze the effects of liraglutide combined with metformin on the immune response in patients with type 2 diabetes mellitus.Methods:150 patients with type 2 diabetes mellitus were randomly divided into experimental group and control group according to the order of admission,75 cases in each group.The control group was treated with metformin,and the treatment group was treated with liraglutide combined with metformin.Statistical analysis was performed using SPSS20.0 statistical software.The clinical effects,average body mass index,blood glucose level(2-hour postprandial blood glucose,glycosylated hemoglobin,fasting blood glucose),immunoglobulin level(IgA,IgG,IgM)and the incidence of adverse reactions such as parameters.Results:(1) There was no significant difference in body mass index(BMI),2-hour postprandial blood glucose,glycosylated hemoglobin,fasting blood glucose,IgA,IgG and IgM levels between the two groups before treatment(P>0.05).After treatment,(P<0.05).The average body mass index(BMI),2-hour postprandial blood glucose,glycosylated hemoglobin(HbA1 c)and fasting blood glucose were significantly higher in the experimental group than those in the control group(P< 0.05).The total effective rate of the experimental group was 94.67%(71/75),the total effective rate of the control group was 77.33%(58/75),the total effective rate of the experimental group was much higher than the control group(P<0.05);(3)The adverse reaction rate was 4.00%(3/75)in the experimental group and 5.33%(4/75)in the control group.There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion:The efficacy of liraglutide combined with metformin in the treatment of type 2 diabetes mellitus is significant,and at the same time,it can effectively improve the immune function.
出处 《陕西医学杂志》 CAS 2018年第1期114-116,共3页 Shaanxi Medical Journal
关键词 糖尿病 2型/药物疗法 二甲双胍/治疗应用 胰高血糖素/治疗应用 @利拉鲁肽 Diabetes mellitus type 2/drug therapy Metformin/therapeutic use Glucagon/therapeutic use @ Liraglutide
  • 相关文献

参考文献12

二级参考文献131

  • 1Diana Boj-Carceller,Pilar Bocos-Terraz,Miguel Moreno-Vernis,Alejandro Sanz-Paris,Pablo Trincado-Aznar,Ramón Albero-Gamboa.Are proton pump inhibitors a new antidiabetic drug? A cross sectional study[J].World Journal of Diabetes,2011,2(12):217-220. 被引量:7
  • 2韦凌云,杨丕坚,李舒敏,吕以培,黄中莹,黄虹.炎症及内皮功能障碍与糖尿病肾病患者尿蛋白的相关性[J].中国老年学杂志,2014,34(9):2445-2447. 被引量:20
  • 3王遂军,贾伟平,包玉倩,陆俊茜,方启晨,陈蕾,陆惠娟,项坤三.血清脂联素与肥胖的关系[J].中华内分泌代谢杂志,2005,21(1):36-38. 被引量:89
  • 4中华医学会糖尿病学分会.中国2型糖尿病防治指南(2010版).北京:北京大学医学出版社,2011.
  • 5Yehuda H, Jeffrey I, Mechaniek MD. AACE Diabetes Care Plan Guidelines. Endoer Pract, 2011, 17(Suppl 2) :1-53.
  • 62011 IDF. Guideline,for Management of Post Meal Glucose in Diabetes. Dubai: IDF,2011.
  • 7Yang W, Ji Q, Zhu D, et al. Biphasic Insulin Aspart 30 Three Times Daily Is More Effective Than a Twice-Daily Regimen, Withoinnotut in Increasing Hypoglyeernia, in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidia-betes Drugs. Diabetes Care, 2008, 31:852-856.
  • 8Jacobsen L. V, Sogaard B, Riis A. Pharmaeokineties and pharmaeodynamies of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharm, 2000, 56: 399-403.
  • 9Shah M. Benroubi V. Borzi J. et al. Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVETM observational study. Int J Clin Pract, 2009, 63:574-582.
  • 10Shestakova M, Sharma S. K, Almustafa M. et al. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Curr Med Res, 2007, 23: 3209-3214.

共引文献261

同被引文献368

引证文献40

二级引证文献303

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部